Figure 3

GBM data results. The posterior probabilities (based on MCMC samples) that β_j,i > δ + ∗ is plotted, where β_j,i is the clinical model regression coefficient for the marker associated with platform j of gene i, and${\delta }_{+}^{\ast }=log(1+\delta )$ is the transformed upper practical cutoff. For our analysis, we use δ = 0.05, which corresponds to a 5% change in survival time, so the posterior probability shown here indicates the probability that a one unit increase in the marker results in at least a 5% increase in survival time. We consider the marker j,i to be significant if this probability is greater than 0.5.